Overview

Dose Proportionality Study Comparing Amaryl-M 1/500 mg and Amaryl-M 2/500 mg

Status:
Completed
Trial end date:
2007-08-01
Target enrollment:
Participant gender:
Summary
The pharmacokinetics of glimepiride and metformin HCl will be compared after single dose intake of both combinations in order to answer the following questions: - Is Amaryl-M 1/500 mg (Test tablet) proportional to Amaryl-M 2/500 mg tablet with regard to the glimepiride component? - Is Amaryl-M 1/500 mg (Test tablet) tolerable comparing with Amaryl-M 2/500 mg?
Phase:
Phase 1
Details
Lead Sponsor:
Handok Inc.
Handok Pharmaceuticals Co., Ltd.
Treatments:
Glimepiride
Metformin